GlassScriptPhysician profile
Saif Jaweed
NPI 1255333472
$12,227.34
in general payments reported to CMS, 2019-2025
35 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $682 · 2021: $2,485 · 2022: $1,300 · 2023: $2,715 · 2024: $2,447 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,670 · Travel and Lodging: $927 · Long Term Medical Supply Or Device Loan: $454 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,669.67 |
| Travel and Lodging | $927.41 |
| Long Term Medical Supply Or Device Loan | $453.50 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,372.03 | 2019-2025 | Veritas Vision System, Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $2,312.65 | 2019-2025 | Clareon, Centurion, Argos |
| Carl Zeiss Meditec USA, INC. | $898.64 | 2021-2025 | Cirrus 5000 With Angioplex, Quatera 700, Veracity Surgical |
| Bausch & Lomb Americas INC. | $890.98 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Halozyme INC | $582.09 | 2019-2025 | Hylenex Recombinant |
| Abbvie INC. | $519.00 | 2022-2025 | |
| New World Medical,INC. | $496.94 | 2021-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Harrow Eye, LLC | $488.23 | 2023-2025 | Vevye, Iheezo, Triesence |
| Allergan, INC. | $418.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $357.34 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $307.06 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $297.36 | 2019-2025 | Idosetr |
| Omeros Corporation | $289.58 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $284.07 | 2020-2025 | Cequa |
| Ivantis, INC | $229.88 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $214.02 | 2022-2025 | Omidria, Rayone Emv, Rayone Spheric |
| Ocular Therapeutix, INC. | $205.36 | 2020-2025 | Dextenza |
| Rxsight INC | $192.01 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Sight Sciences, INC. | $98.96 | 2020-2025 | Omni Surgical System |
| Amgen INC. | $96.58 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $81.67 | 2019-2023 | |
| Lensar, INC. | $74.59 | 2024 | Lensar Laser System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.88 | 2020-2021 | |
| Shire North American Group INC | $67.31 | 2019 | |
| Astellas Pharma US INC | $61.86 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $54.44 | 2024-2025 | Acthar |
| Lumibird Medical INC. | $49.04 | 2019-2020 | |
| Dompe US, INC. | $43.81 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $36.85 | 2020 | |
| Horizon Therapeutics Plc | $34.46 | 2019-2023 | Tepezza |
| Lombart Brothers, INC. | $27.44 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $26.36 | 2022 | |
| Tearlab Corp | $22.62 | 2024 | Scoutpro Osmolarity System |
| Kala Pharmaceuticals, INC. | $15.54 | 2021 | |
| Beaver-Visitec International, INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saif Jaweed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.